Blog Big Molecule Watch March 04, 2022

Biocon Biologics Ltd. To Acquire Viatris Biosimilars Portfolio

On Monday, Biocon Biologics Limited (Biocon) announced that it will acquire Viatris’ rights in biosimilars assets for up to $3.3 billion.

Viatris and Biocon previously partnered to bring SEMGLEE to market in the U.S.  SEMGLEE (insulin glargine-yfgn) injection launched last year in the U.S. as the first-ever interchangeable biosimilar approved by the FDA.  Viatris’ portfolio also includes HULIO, a biosimilar to AbbVie’s HUMIRA (adalimumab).  Under a license agreement with AbbVie, HULIO can launch in the U.S. in July 2023.

The post Biocon Biologics Ltd. To Acquire Viatris Biosimilars Portfolio appeared first on Big Molecule Watch.